Читать книгу Surgical Management of Advanced Pelvic Cancer - Группа авторов - Страница 54

1 1 Sauer, R., Liersch, T., Merkel, S. et al. (2012). Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO‐94 randomized phase III trial after a median follow‐up of 11 years. J. Clin. Oncol. 30: 1926–1933.

2 2 Peeters, K.C.M.J., Marijnen, C.A.M., Nagtegaal, I.D. et al. (2007). The TME trial after a median follow‐up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246: 693–701.

3 3 Swedish Rectal Cancer Trial, Cedermark, B., Dahlberg, M. et al. (1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med. 336: 980–987.

4 4 Folkesson, J., Birgisson, H., Pahlman, L. et al. (2005). Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23: 5644–5650.

5 5 Bosset, J.‐F., Collette, L., Calais, G. et al. (2006). Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355: 1114–1123.

6 6 Peacock, O., Waters, P.S., Bressel, M. et al. (2019). Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era. Br. J. Surg. 106: 1685–1696.

7 7 André, T., de Gramont, A., Vernerey, D. et al. (2015). Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10‐year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33: 4176–4187.

8 8 Kuebler, J.P., Wieand, H.S., O’Connell, M.J. et al. (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C‐07 J. Clin. Oncol. 25: 2198–2204.

9 9 Krook, J.E., Moertel, C.G., Gunderson, L.L. et al. (1991). Effective surgical adjuvant therapy for high‐risk rectal carcinoma.N. Engl. J.Med. 324: 709–715.

10 10 Petersen, S.H., Harling, H., Kirkeby, L.T. et al. (2012). Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst. Rev. 3: CD004078.

11 11 Hong, Y.S., Nam, B.‐H., Kim, K.‐P. et al. (2014). Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open‐label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 15: 1245–1253.

12 12 Sainato, A., Cernusco Luna Nunzia, V., Valentini, V. et al. (2014). No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I‐CNR‐RT). Radiother. Oncol. J. 113: 223–229.

13 13 Glynne‐Jones, R., Counsell, N., Quirke, P. et al. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann. Oncol. 25: 1356–1362.

14 14 Breugom, A.J., van Gijn, W., Muller, E.W. et al. (2015). Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann. Oncol. Off. 26: 696–701.

15 15 Bosset, J.‐F., Calais, G., Mineur, L. et al. (2014). Fluorouracil‐based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long‐term results of the EORTC 22921 randomised study. Lancet Oncol. 15: 184–190.

16 16 Biagi, J.J., Raphael, M.J., Mackillop, W.J. et al. (2011). Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta‐analysis. JAMA 305: 2335–2342.

17 17 Martin, S.T., Heneghan, H.M., and Winter, D.C. (2012). Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J.Surg. 99: 918–928.

18 18 Kenis, C., Decoster, L., Van Puyvelde, K. et al. (2014). Performance of two geriatric screening tools in older patients with cancer. J. Clin. Oncol. 32: 19–26.

19 19 Maas, M., Nelemans, P.J., Valentini, V. et al. (2010). Long‐term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11: 835–844.

20 20 Kalady, M.F., de Campos‐Lobato, L.F., Stocchi, L. et al. (2009). Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann. Surg. 250: 582–589.

21 21 Tulchinsky, H., Shmueli, E., Figer, A. et al. (2008). An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease‐free survival in patients with locally advanced rectal cancer. Ann. Surg. Oncol. 15: 2661–2667.

22 22 Ryan, É.J., O’Sullivan, D.P., Kelly, M.E. et al. (2019). Meta‐analysis of the effect of extending the interval after long‐course chemoradiotherapy before surgery in locally advanced rectal cancer. Br. J. Surg. 106: 1298–1310.

23 23 Lefevre, J.H., Mineur, L., Kotti, S. et al. (2016). Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR‐6) J. Clin. Oncol. 34: 3773–3780.

24 24 Perez, K., Safran, H., Sikov, W. et al. (2017). Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE study. Am. J. Clin. Oncol. 40: 283–287.

25 25 Garcia‐Aguilar, J., Chow, O.S., Smith, D.D. et al. (2015). Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16: 957–966.

26 26 Fernandez‐Martos, C., Garcia‐Albeniz, X., Pericay, C. et al. (2015). Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long‐term results of the Spanish GCR‐3 phase II randomized trial. Ann. Oncol. 26: 1722–1728.

27 27 Hardiman, K.M., Antunez, A.G., Kanters, A. et al. (2019). Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally‐advanced rectal cancer. J. Surg. Oncol. 120: 308–315.

28 28 Zaborowski, A., Stakelum, A., and Winter, D.C. (2019). Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. Br. J. Surg. 106: 979–987.

29 29 Petrelli, F., Trevisan, F., Cabiddu, M. et al. (2020). Total neoadjuvant therapy in rectal cancer: a systematic review and meta‐analysis of treatment outcomes. Ann. Surg. 271: 440–448.

30 30 Hospers, G., Bahadoer, R.R., Dijkstra, E.A. et al. (2020). Short‐course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. J. Clin. Oncol. 38: 4006.

31 31 Conroy, T., Lamfichekh, N., Etienne, P.‐L. et al. (2020). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J. Clin. Oncol. 38: 4007.

32 32 Marco, M.R., Zhou, L., Patil, S. et al. (2018). Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis. Colon Rectum 61: 1146–1155.

33 33 Markovina, S., Youssef, F., Roy, A. et al. (2017). Improved metastasis‐ and disease‐free survival with preoperative sequential short‐course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long‐course chemoradiotherapy: results of a matched pair analysis. Int. J. Radiat. Oncol. Biol. Phys. 99: 417–426.

34 34 Zheng, R., Lian, S., Huang, X. et al. (2019). The survival benefit of intensified full‐dose XELOX chemotherapy concomitant to radiotherapy and then resting‐period consolidation chemotherapy in locally advanced rectal cancer. J. Cancer 10: 730–736.

35 35 Ciseł, B., Pietrzak, L., Michalski, W. et al. (2019). Long‐course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long‐term results of the randomized Polish II study. Ann. Oncol. 30: 1298–1303.

36 36 Zampino, M.G., Magni, E., Leonardi, M.C. et al. (2009). Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 75: 421–427.

37 37 Yu, X., Wang, Q., Xiao, W. et al. (2018). Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single‐institute phase II study. Cancer Commun. 38: 24.

38 38 CLC, B., Lunniss, P.J., Knowles, C.H. et al. (2012). Anterior resection syndrome. Lancet Oncol. 13: e403–e408.

39 39 EHA, P., Palmer, G.J., Juul, T. et al. (2019). Low anterior resection syndrome and quality of life after sphincter‐sparing rectal cancer surgery: a long‐term longitudinal follow‐up. Dis. Colon Rectum 62: 14–20.

40 40 van Heinsbergen, M., Janssen‐Heijnen, M.L., Leijtens, J.W. et al. (2018). Bowel dysfunction after sigmoid resection underestimated: multicentre study on quality of life after surgery for carcinoma of the rectum and sigmoid. Eur. J. Surg. Oncol. 44: 1261–1267.

41 41 van der Valk, M.J.M., Hilling, D.E., Bastiaannet, E. et al. (2018). Long‐term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391: 2537–2545.

42 42 Cercek, A., CSD, R., Strombom, P. et al. (2018). Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 4: e180071.

43 43 Garcia‐Aguilar, J., Patil, S., Kim, J.K. et al. (2020). Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J. Clin. Oncol. 38: 4008.

44 44 Smith, J.J., Chow, O.S., Gollub, M.J. et al. (2015). Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3‐year disease‐free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15: 767.

45 45 Rödel, C., Graeven, U., Fietkau, R. et al. (2015). Oxaliplatin added to fluorouracil‐based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO‐04 study): final results of the multicentre, open‐label, randomised, phase 3 trial. Lancet Oncol. 16: 979–989.

46 46 Gérard, J.‐P., Azria, D., Gourgou‐Bourgade, S. et al. (2012). Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. Off. 30: 4558–4565.

47 47 Aschele, C., Cionini, L., Lonardi, S. et al. (2011). Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR‐01 randomized phase III trial. J. Clin. Oncol. 29: 2773–2780.

48 48 Allegra, C.J., Yothers, G., O’Connell, M.J. et al. (2015). Neoadjuvant 5‐FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J. Natl Cancer Inst. 107.

49 49 Hüttner, F.J., Probst, P., Kalkum, E. et al. (2019). Addition of platinum derivatives to fluoropyrimidine‐based neoadjuvant chemoradiotherapy for stage II/III rectal cancer: systematic review and meta‐analysis. J. Natl Cancer Inst. 111: 887–902.

50 50 Fu, X.‐L., Fang, Z., Shu, L.‐H. et al. (2017). Meta‐analysis of oxaliplatin‐based versus fluorouracil‐based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Oncotarget 8: 34340–34351.

51 51 Dueland, S., Ree, A.H., Grøholt, K.K. et al. (2016). Oxaliplatin‐containing preoperative therapy in locally advanced rectal cancer: local response, toxicity and long‐term outcome. Clin. Oncol. R. Coll. Radiol. 28: 532–539.

52 52 Kogler, P., AF, D.V., Eisterer, W. et al. (2018). Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer: impact on long‐term outcome. Results of the phase II TAKO 05/ABCSG R‐02 trial. Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al 194: 41–49.

53 53 Fernández‐Martos, C., Pericay, C., Aparicio, J. et al. (2010). Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging‐defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J. Clin. Oncol. 28: 859–865.

54 54 Clifford, R., Govindarajah, N., Parsons, J.L. et al. (2018). Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. Br. J. Surg. 105: 1553–1572.

55 55 Willett, C.G., Boucher, Y., di Tomaso, E. et al. (2004). Direct evidence that the VEGF‐specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10: 145–147.

56 56 Zhong, X., Wu, Z., Gao, P. et al. (2018). The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta‐analysis. Cancer Med. 7: 565–582.

57 57 Konishi, T., Shinozaki, E., Murofushi, K. et al. (2019). Phase II trial of neoadjuvant chemotherapy, chemoradiotherapy, and laparoscopic surgery with selective lateral node dissection for poor‐risk low rectal cancer. Ann. Surg. Oncol. 26: 2507–2513.

58 58 Conroy, T., Hammel, P., Hebbar, M. et al. (2018). FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379: 2395–2406.

59 59 Masi, G., Vivaldi, C., Fornaro, L. et al. (2019). Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur. J. Cancer Oxf. Engl. 110: 32–41.

60 60 Fernández‐Martos, C., Pericay, C., Losa, F. et al. (2019). Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high‐risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 5 (11): 1566–1573.

61 61 Dewdney, A., Cunningham, D., Tabernero, J. et al. (2012). Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high‐risk rectal cancer (EXPERT‐C). J. Clin. Oncol. 30: 1620–1627.

62 62 Nogué, M., Salud, A., Vicente, P. et al. (2011). Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine‐based chemoradiotherapy in magnetic resonance imaging–defined poor‐prognosis locally advanced rectal cancer: the AVACROSS study. The Oncologist 16: 614–620.

63 63 George, T.J., Yothers, G., Hong, T.S. et al. (2019). NRG‐GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—first experimental arm (EA) initial results. J. Clin. Oncol. 15: 3505.

64 64 Le, D.T., Uram, J.N., Wang, H. et al. (2015). PD‐1 blockade in tumors with mismatch‐repair deficiency. New Engl. J.Med. 372: 2509–2520.

65 65 André, T., Shiu, K.‐K., Kim, T.W. et al. (2020). Pembrolizumab in microsatellite‐instability–high advanced colorectal cancer. N. Engl. J. Med. 383: 2207–2218.

66 66 Zhang, J., Cai, J., Deng, Y., and Wang, H. (2019). Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab. Oncoimmunology 8.

67 67 Chiang, S.‐F., Huang, C.‐Y., Ke, T.‐W. et al. (2019). Upregulation of tumor PD‐L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol. Immunother. 68: 283–296.

68 68 Hecht, M., Büttner‐Herold, M., Erlenbach‐Wünsch, K. et al. (1990). PD‐L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur. J. Cancer Oxf. Engl. 65: 52–60.

69 69 Salvatore, L., Bensi, M., Pietrantonio, F. et al. (2019). 662TiP—phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA Study. Ann. Oncol. 30: v249.

70 70 Cohen, R., Shi, Q., and André, T. (2020). Immunotherapy for early stage colorectal cancer: a glance into the future. Cancers 12.

71 71 Arnold, C.R., Mangesius, J., Jäger, R., and Ganswindt, U. (2020). Neoadjuvant chemoradiotherapy in rectal cancer. Mag. Eur. Med. Oncol. 13: 329–333.

72 72 Kössler, T., Buchs, N., Dutoit, V. et al. (2020). P‐115 PEMREC: a phase II study to evaluate safety and efficacy of neo‐adjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal cancer. Ann. Oncol. 31: S127.

73 73 Antonia, S.J., Villegas, A., Daniel, D. et al. (2018). Overall survival with durvalumab after chemoradiotherapy in stage III. N. Engl. J. Med. 379: 2342–2350.

74 74 van Zoggel, D.M.G.I., Bosman, S.J., Kusters, M. et al. (2018). Preliminary results of a cohort study of induction chemotherapy‐based treatment for locally recurrent rectal cancer. Br. J. Surg. 105: 447–452.

75 75 Bossé, D., Mercer, J., Raissouni, S. et al. (2016). PROSPECT eligibility and clinical outcomes: results from the Pan‐Canadian Rectal Cancer Consortium. Clin. Colorectal Cancer 15: 243–249.

76 76 Rullier, E., Rouanet, P., Tuech, J.‐J. et al. (2017). Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open‐label, multicentre, phase 3 trial. Lancet 390: 469–479.

77 77 Rullier, E., Vendrely, V., Asselineau, J. et al. (2020). Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5‐year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol. Hepatol. 5: 465–474.

78 78 Anon. Circulating tumor DNA testing in predicting treatment for patients with stage IIA colon cancer after surgery. 2019. www.ClinicalTrials.gov.

79 79 Folprecht, G., Reinacher‐Schick, A., Tannapfel, A. et al. (2020). Circulating tumor DNA‐based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE‐trial) AIO‐KRK‐0217. J. Clin. Oncol. 38: TPS273.

80 80 Siena, S., di Bartolomeo, M., Raghav, K.P.S. et al. (2020). A phase II, multicenter, open‐label study of trastuzumab deruxtecan (T‐DXd; DS‐8201) in patients (pts) with HER2‐expressing metastatic colorectal cancer (mCRC): DESTINY‐CRC01. J. Clin. Oncol. 38 (15): 4000.

81 81 Akiyoshi, T., Tanaka, N., Kiyotani, K. et al. (2019). Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br. J. Surg. 106: 1381–1392.

82 82 Koyama, F.C., Ramos, C.M.L., Ledesma, F. et al. (2018). Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. Br. J. Surg. 105: e192–e203.